Mahamaya Lifesciences Ltd
ncorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management.[1]
- Market Cap ₹ 422 Cr.
- Current Price ₹ 180
- High / Low ₹ 205 / 111
- Stock P/E 25.6
- Book Value ₹ 52.1
- Dividend Yield 0.00 %
- ROCE 20.0 %
- ROE 19.3 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals
Part of BSE SME IPO
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 90 | 137 | 161 | 266 | 329 | |
| Sales growth | +53% | +18% | +64% | +24% | |
| 84 | 128 | 148 | 241 | 296 | |
| Operating Profit | 6 | 9 | 13 | 25 | 34 |
| OPM % | 7% | 6% | 8% | 9% | 10% |
| 0 | 0 | 1 | 1 | 1 | |
| Interest | 2 | 3 | 6 | 7 | 8 |
| Depreciation | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | 4 | 5 | 7 | 17 | 24 |
| Tax % | 27% | 26% | 27% | 26% | 31% |
| 3 | 4 | 5 | 13 | 17 | |
| EPS in Rs | 1.99 | 2.74 | 3.81 | 7.21 | 7.06 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 34% |
| TTM: | 24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 64% |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 24% |
| Last Year: | 19% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 18 | 23 |
| Reserves | 14 | 18 | 23 | 32 | 99 |
| 19 | 24 | 55 | 58 | 91 | |
| 21 | 34 | 33 | 81 | 98 | |
| Total Liabilities | 56 | 78 | 112 | 188 | 310 |
| 20 | 21 | 21 | 27 | 35 | |
| CWIP | 2 | 2 | 3 | 4 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 34 | 54 | 88 | 157 | 267 | |
| Total Assets | 56 | 78 | 112 | 188 | 310 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 2 | 1 | -23 | -0 | -30 | |
| -3 | -3 | -2 | -7 | -16 | |
| 1 | 2 | 24 | 9 | 81 | |
| Net Cash Flow | 0 | 1 | -0 | 1 | 35 |
| Free Cash Flow | -1 | -2 | -25 | -5 | -38 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 56% | 24% | -162% | 6% | -75% |
Ratios
Consolidated / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 37 | 25 | 64 | 67 | 78 |
| Inventory Days | 93 | 109 | 137 | 167 | 194 |
| Days Payable | 83 | 87 | 61 | 92 | 88 |
| Cash Conversion Cycle | 47 | 48 | 140 | 142 | 184 |
| Working Capital Days | 8 | 9 | 14 | 29 | 49 |
| ROCE % | 20% | 21% | 26% | 20% |
Documents
Announcements
-
Board Meeting Intimation for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Half Year Ended September 30, 2026.
- Board meets November 13, 2026 to approve H1 FY2027 unaudited standalone and consolidated results.
-
Non-Applicability Of The Compliance On Corporate Governance For The Quarter Ended September 30, 2026
- Mahamaya Lifesciences says corporate governance report not applicable for quarter ended 30 September 2026.
-
Publication Of Executive Interview In Agropages Magazine (2026 India Focus Issue)
- Executive interview published in AgroPages 2026 India Focus Issue on October 9, 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
-
Announcement under Regulation 30 (LODR)-Change in Management
- Mahamaya Lifesciences approved multiple board changes, including new chairman and managing director from Nov 1, 2026.
Business Profile[1]
The company manufactures pesticide formulations and supplies bulk products to Indian agrochemical companies and multinational corporations (MNCs). It imports scientifically researched molecules, secures registrations with the Central Insecticides Board, and develops these molecules into technical-grade and value-added formulations, which are marketed to domestic manufacturers and global MNCs.